LRPA
BMY.RT

L. Roy Papp & Associates’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

L. Roy Papp & Associates’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-16,530
Closed -$50K – 176
2019
Q4 		$50K Buy
+16,530
New +$43K 0.01% 176

Other funds holding BMY.RT

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

L. Roy Papp & Associates's BMY.RT Position: Q1 2020 in Review

L. Roy Papp & Associates sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2020, closing a stake of 16,530 shares — an estimated $50K sold.

L. Roy Papp & Associates first reported a position in BMY.RT in Q4 2019 and held it in 1 quarter. The position peaked at $50K in Q4 2019. 581 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2020.

  • L. Roy Papp & Associates reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • L. Roy Papp & Associates sold 16,530 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2020, an estimated $50K.
  • L. Roy Papp & Associates first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 1 quarter.
  • L. Roy Papp & Associates's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $50K in Q4 2019.
  • 581 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2020.

Based on L. Roy Papp & Associates's 13F filing for Q1 2020, filed 5 May 2020.